tic aminoglycoside antibiotic, with a potency and breadth of spectrum similar to that of amikacin (8). This compound has been evaluated for cochlear toxicity in neonatal guinea pigs, in comparison with amikacin, gentamicin, and kanamycin A.
MATERIALS AND METHODS Redfern strain (Pfizer colony) albino guinea pigs were used. They were taken within 48 h of birth, sexed, weighed, ear-tagged, and assigned to groups of five to six animals. When not engaged in the screening procedure, animals were housed with their respective sows.
Auditory function. The apparatus used consisted of a Levell R.C. oscillator (type T.G. 200; Levell Electronics Ltd., Barnet, Hertfordshire, England), which delivered a pure sine-wave signal of adjustable frequency to a 15-W amplifier/control unit designed and constructed in our instrument laboratory. were administered for up to 40 days. At these dose levels none of the antibiotics had any effect VOL. 16, 1979 on Preyer's reflex for the first 25 to 30 days of treatment, after which time the mean threshold sound intensities began to rise slowly in all drugtreated groups (Fig. 1) . All compounds had a greater effect on the response to higher frequencies (Fig. 2) .
When the four antibiotics were administered for up to 40 days at either 100 mg/kg per day (butikacin, amikacin, and kanamycin A) or 33.3 mg/kg per day (gentamicin), there was a greater differentiation. Although thresholds at 12 kHz began to rise between days 12 and 15, complete loss of Preyer's reflex at this frequency required treatment for 23 days with amikacin, 33 days with butikacin, and 40 days with kanamycin A. In contrast, only one animal in the gentamicin group had complete loss of Preyer's reflex at 12 kHz within the 40 days of the experiment (Fig.  3) . After 30 days of treatment, amikacin had produced the largest threshold shift, followed by butikacin and kanamycin A; gentamicin produced the smallest change (Fig. 4) . As at the lower dose levels, the higher frequencies tended to be affected most.
At the highest dose levels studied (200 mg of butikacin, amikacin, and kanamycin A per kg per day or 66.6 mg of gentamicin per kg per day), all compounds produced similar responses, with rapid loss of Preyer's reflex at 12 kHz occurring within 17 days (Fig. 5) . However, after 10 days of treatment, there was a greater threshold shift for kanamycin A and amikacin than for butikacin or gentamicin (Fig. 6) . up to 40 days. All four aminoglycosides produced dose-related hearing loss, as measured by the change of threshold sound intensity for Preyer's reflex.
Butikacin was consistently less cochleotoxic than amikacin. At the 200 mg/kg per day dose level, for example, there was a difference ofthree days in the time required to produce complete loss of Preyer's reflex at 12 kHz. Furthermore, after 10 days of treatment, the mean threshold shifts at all frequencies were greater in the amikacin-treated group. At the 100 mg/kg per day dose level, the difference between the two compounds in the duration of treatment required for loss of Preyer's reflex at 12 kHz was 10 days and the threshold shifts were again more marked after amikacin. Comparison of the two compounds at 50 mg/kg per day was difficult, as changes in threshold sound intensities were small. However, there was some indication of a slightly greater effect with amikacin, especially at the highest frequency used.
Kanamycin A tended to fall between the two, being like amikacin at the 200 mg/kg per day dose level and like butikacin at the 100 mg/kg per day dose level. However, it had less effect than either amikacin or butikacin at the lowest dose level. Gentamicin, which was studied at dose levels reflecting its greater antibacterial potency, was the least cochleotoxic, which is consistent with its known more marked effect on the vestibular system (10).
Amikacin and kanamycin A have been shown by other workers to produce similar levels of ototoxicity in animals (7), which is consistent with the results of the present study. This is further borne out by the incidence of ototoxic side effects found in patients treated with amikacin and kanamycin A (9) . It is considered that butikacin will probably have an ototoxic poten- JF-20-
